EG25009A - Aniline derived ligands for the thyroid receptor. - Google Patents
Aniline derived ligands for the thyroid receptor.Info
- Publication number
- EG25009A EG25009A EG20010132A EG20010132A EG25009A EG 25009 A EG25009 A EG 25009A EG 20010132 A EG20010132 A EG 20010132A EG 20010132 A EG20010132 A EG 20010132A EG 25009 A EG25009 A EG 25009A
- Authority
- EG
- Egypt
- Prior art keywords
- thyroid receptor
- derived ligands
- aniline derived
- aniline
- ligands
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/27—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18322300P | 2000-02-17 | 2000-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
EG25009A true EG25009A (en) | 2011-05-16 |
Family
ID=22671959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EG20010132A EG25009A (en) | 2000-02-17 | 2001-02-14 | Aniline derived ligands for the thyroid receptor. |
Country Status (30)
Country | Link |
---|---|
US (2) | US6800605B1 (xx) |
EP (1) | EP1257526B1 (xx) |
JP (1) | JP4629294B2 (xx) |
KR (1) | KR100740383B1 (xx) |
CN (1) | CN1216857C (xx) |
AR (1) | AR031094A1 (xx) |
AT (1) | ATE295348T1 (xx) |
AU (2) | AU2001230929B2 (xx) |
BR (1) | BR0108134A (xx) |
CA (1) | CA2400486C (xx) |
CO (1) | CO5271672A1 (xx) |
CZ (1) | CZ20022771A3 (xx) |
DE (1) | DE60110753T2 (xx) |
DK (1) | DK1257526T3 (xx) |
EG (1) | EG25009A (xx) |
ES (1) | ES2242723T3 (xx) |
HK (1) | HK1047925B (xx) |
HU (1) | HUP0301777A3 (xx) |
IL (2) | IL150449A0 (xx) |
MX (1) | MXPA02007929A (xx) |
MY (1) | MY124534A (xx) |
NO (1) | NO329639B1 (xx) |
NZ (1) | NZ520023A (xx) |
PE (1) | PE20020767A1 (xx) |
PL (1) | PL201790B1 (xx) |
PT (1) | PT1257526E (xx) |
RU (1) | RU2260586C2 (xx) |
UY (1) | UY26581A1 (xx) |
WO (1) | WO2001060784A1 (xx) |
ZA (1) | ZA200206072B (xx) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6664291B2 (en) | 2000-03-31 | 2003-12-16 | Pfizer, Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
DE10131462A1 (de) * | 2001-06-29 | 2003-01-09 | Bayer Ag | Phenol-Derivate |
US6806381B2 (en) | 2001-11-02 | 2004-10-19 | Bristol-Myers Squibb Company | Process for the preparation of aniline-derived thyroid receptor ligands |
US20040242594A1 (en) * | 2001-11-17 | 2004-12-02 | Dan Peters | Prodrugs of antidepressants and their use for treating depressions |
GB0208384D0 (en) * | 2002-04-11 | 2002-05-22 | Karobio Ab | Novel compounds |
JP2006516620A (ja) * | 2003-01-24 | 2006-07-06 | ブリストル−マイヤーズ スクイブ カンパニー | 甲状腺受容体におけるシクロアルキル含有アニリドリガンド |
TW200504021A (en) | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
EP1660090B1 (en) * | 2003-08-14 | 2012-11-21 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
WO2005051298A2 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
GB0406378D0 (en) * | 2004-03-22 | 2004-04-21 | Karobio Ab | Novel pharmaceutical compositions |
CA2606499C (en) | 2005-05-26 | 2017-06-13 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
GB0606201D0 (en) | 2006-03-28 | 2006-05-10 | Karobio Ab | Improved crytalline material |
GB0606212D0 (en) * | 2006-03-28 | 2006-05-10 | Karobio Ab | Pharmaceutical compositions |
US20070238770A1 (en) * | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
GB0724478D0 (en) * | 2007-12-14 | 2008-01-30 | Karobio Ab | Pharmaceutical compositions |
US20090197947A1 (en) * | 2008-02-01 | 2009-08-06 | The Research Foundation Of State University Of New York | Medicaments and methods for lowering plasma lipid levels and screening drugs |
US8922530B2 (en) * | 2010-01-06 | 2014-12-30 | Apple Inc. | Communicating stylus |
EP2609910A1 (en) * | 2011-12-30 | 2013-07-03 | Deva Holding Anonim Sirketi | Formulations of eprotirome |
PL2695611T3 (pl) | 2012-08-06 | 2015-03-31 | Dr August Wolff Gmbh & Co Kg Arzneimittel | Eprotirom do stosowania w profilaktyce i/lub leczeniu zaburzeń włosów oraz jego kompozycje |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
CN113277958A (zh) * | 2016-05-18 | 2021-08-20 | 俄勒冈健康科学大学 | 苏比替罗衍生物 |
KR20190104524A (ko) | 2016-11-21 | 2019-09-10 | 바이킹 테라퓨틱스 인코포레이티드 | 당원축적질환의 치료 방법 |
KR102600115B1 (ko) | 2017-06-05 | 2023-11-09 | 바이킹 테라퓨틱스 인코포레이티드 | 섬유증 치료를 위한 조성물 |
EP3768690A4 (en) | 2018-03-22 | 2021-11-24 | Viking Therapeutics, Inc. | CRYSTALLINE SHAPES AND METHOD FOR MAKING CRYSTALLINE SHAPES OF A COMPOUND |
CN113423684A (zh) * | 2018-12-12 | 2021-09-21 | 速通医疗公司 | 新型拟甲状腺素药 |
WO2020169069A1 (en) | 2019-02-21 | 2020-08-27 | Nanjing Ruijie Pharma Co., Ltd. | Novel compounds and their uses as thyroid hormone receptor agonists |
CA3130371A1 (en) | 2019-03-01 | 2020-09-10 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
KR20230048481A (ko) | 2020-06-02 | 2023-04-11 | 쳉두 캉홍 파마슈티칼 코., 엘티디. | 새로운 갑상선 호르몬 β 수용체 효능제 |
WO2023177667A1 (en) * | 2022-03-16 | 2023-09-21 | Brii Biosciences, Inc. | Thyroid hormone receptor agonists |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1078582B (de) * | 1958-10-29 | 1960-03-31 | Hoechst Ag | Verfahren zur Herstellung substituierter Thyropropionsaeuren |
JPS6061747A (ja) * | 1983-09-16 | 1985-04-09 | Konishiroku Photo Ind Co Ltd | 熱現像感光材料 |
ES2108855T3 (es) | 1992-07-21 | 1998-01-01 | Ciba Geigy Ag | Derivados de acido oxamico como agentes hipocolesteremicos. |
GB9713739D0 (en) * | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
NZ513449A (en) | 1999-03-01 | 2004-02-27 | Pfizer Prod Inc | Oxamic acids and derivatives as thyroid receptor ligands |
ES2234523T3 (es) | 1999-03-01 | 2005-07-01 | Pfizer Products Inc. | Acidos oxamicos que contienen ciano y sus derivados como ligandos de receptores tiroideos. |
CO5160290A1 (es) | 1999-03-29 | 2002-05-30 | Novartis Ag | Derivados de acido fenoxifeniloxamico sustituido . |
DK1088819T3 (da) | 1999-09-30 | 2005-09-12 | Pfizer Prod Inc | 6-azauracilderivater som thyroidreceptorligander |
US6664291B2 (en) | 2000-03-31 | 2003-12-16 | Pfizer, Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
ATE382602T1 (de) * | 2000-03-31 | 2008-01-15 | Pfizer Prod Inc | Malonsäureamide sowie deren derivate als thyroidrezeptor liganden |
AU4884701A (en) * | 2000-05-12 | 2001-11-20 | Kissei Pharmaceutical Co. Ltd. | Malonanilic acid derivatives, medicinal compositions containing the same and usethereof |
WO2002094319A1 (en) * | 2001-05-18 | 2002-11-28 | Kissei Pharmaceutical Co., Ltd. | Preventive or recurrence-suppressive agents for liver cancer |
TW200504021A (en) * | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
-
2001
- 2001-01-12 BR BR0108134-9A patent/BR0108134A/pt not_active Application Discontinuation
- 2001-01-12 CZ CZ20022771A patent/CZ20022771A3/cs unknown
- 2001-01-12 JP JP2001559838A patent/JP4629294B2/ja not_active Expired - Fee Related
- 2001-01-12 AU AU2001230929A patent/AU2001230929B2/en not_active Ceased
- 2001-01-12 CN CN018050689A patent/CN1216857C/zh not_active Expired - Fee Related
- 2001-01-12 ES ES01903064T patent/ES2242723T3/es not_active Expired - Lifetime
- 2001-01-12 EP EP01903064A patent/EP1257526B1/en not_active Expired - Lifetime
- 2001-01-12 AU AU3092901A patent/AU3092901A/xx active Pending
- 2001-01-12 HU HU0301777A patent/HUP0301777A3/hu unknown
- 2001-01-12 RU RU2002123349/04A patent/RU2260586C2/ru not_active IP Right Cessation
- 2001-01-12 PL PL366149A patent/PL201790B1/pl not_active IP Right Cessation
- 2001-01-12 MX MXPA02007929A patent/MXPA02007929A/es active IP Right Grant
- 2001-01-12 PT PT01903064T patent/PT1257526E/pt unknown
- 2001-01-12 DK DK01903064T patent/DK1257526T3/da active
- 2001-01-12 CA CA2400486A patent/CA2400486C/en not_active Expired - Fee Related
- 2001-01-12 KR KR1020027010684A patent/KR100740383B1/ko not_active IP Right Cessation
- 2001-01-12 WO PCT/US2001/001204 patent/WO2001060784A1/en active IP Right Grant
- 2001-01-12 NZ NZ520023A patent/NZ520023A/en not_active IP Right Cessation
- 2001-01-12 DE DE60110753T patent/DE60110753T2/de not_active Expired - Lifetime
- 2001-01-12 AT AT01903064T patent/ATE295348T1/de active
- 2001-01-12 IL IL15044901A patent/IL150449A0/xx active IP Right Grant
- 2001-01-16 US US09/761,050 patent/US6800605B1/en not_active Expired - Lifetime
- 2001-01-31 MY MYPI20010445A patent/MY124534A/en unknown
- 2001-02-14 EG EG20010132A patent/EG25009A/xx active
- 2001-02-14 UY UY26581A patent/UY26581A1/es not_active Application Discontinuation
- 2001-02-15 CO CO01012101A patent/CO5271672A1/es not_active Application Discontinuation
- 2001-02-16 AR ARP010100730A patent/AR031094A1/es active IP Right Grant
- 2001-02-16 PE PE20010001762002000058A patent/PE20020767A1/es not_active Application Discontinuation
-
2002
- 2002-06-27 IL IL150449A patent/IL150449A/en not_active IP Right Cessation
- 2002-07-30 ZA ZA200206072A patent/ZA200206072B/en unknown
- 2002-08-16 NO NO20023895A patent/NO329639B1/no not_active IP Right Cessation
-
2003
- 2003-01-03 HK HK03100094.2A patent/HK1047925B/zh not_active IP Right Cessation
-
2004
- 2004-08-30 US US10/930,360 patent/US7109164B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EG25009A (en) | Aniline derived ligands for the thyroid receptor. | |
HUP0104666A3 (en) | Thyroid receptor ligands | |
HK1042488A1 (en) | 1-Heterocycle substituted diarylamines. | |
MXPA03009791A (es) | Ligandos para el receptor de melanocortina. | |
AU8066701A (en) | Capsaicin receptor ligands | |
ZA200107411B (en) | Melanocortin receptor ligands. | |
ZA200203450B (en) | beta2-adrenergic receptor agonists. | |
MXPA03007078A (es) | Ligandos del receptor de canabinoide. | |
ZA200206768B (en) | Aryl fused azapolycyclic compounds. | |
MXPA01013362A (es) | Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso. | |
MXPA03004527A (es) | Compuestos antagonicos lfa-1. | |
HK1044757A1 (en) | Pyrimidinone compounds. | |
HK1054384A1 (en) | 4-Pyrimidinyl-n-acyl-l-phenylalanines. | |
HK1053470A1 (en) | 4-Pyridinyln-acyl-l-phenylalanines. | |
ZA200108968B (en) | New compounds. | |
IL157031A0 (en) | Thyroid receptor ligands | |
EP1601641A4 (en) | SUBSTITUTED ANILID BINDER FOR THE THYROID RECEPTOR | |
ZA992596B (en) | Azabicyclic 5HT1 receptor ligands. | |
ZA200106875B (en) | Trace elements. | |
ZA200200784B (en) | Calcilytic compounds. | |
ZA200108129B (en) | Histidine protein-phosphatase. | |
ZA200107421B (en) | Complexing agents. | |
ZA200005361B (en) | Positioning arrangement. | |
ZA986876B (en) | 1-Phenyl-4-benzylpiperazines; dopamine receptor subtype specific ligands. | |
ZA200004838B (en) | Electromembrane. |